The biotechnology company MedDay, recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials of its drug product MD1003 in patients with multiple sclerosis (MS).
Specifically, the trials included people with “not active” progressive MS and those with either relapsing or progressive MS and visual loss, respectively. Data presented at the recent American Academy of Neurology 2016 Annual Meeting in Vancouver, Canada, demonstrated better efficacy in reversing disease progression than a drug has previously achieved in not-active progressive MS.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?